Idiopathic Pulmonary Fibrosis
Conditions
Brief summary
Post-marketing surveillance of Pirfenidone
Detailed description
Pirfenidone (Pirespa®) is an anti fibrotic drug, which was approved in 2012 in the Republic of Korea for the treatment of patients with idiopathic pulmonary fibrosis (IPF). A post-marketing survey was conducted following the approval to obtain data on the safety and efficacy of pirfenidone for IPF treatment in real-world practice.
Interventions
OTHERNA(observation study)
NA(observation study)
Sponsors
IlDong Pharmaceutical Co Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Among patients diagnosed as idiopathic pulmonary fibrosis, only those who have used the testing drug under the general medical conditions for a certain investigation period after the beginning of the investigation and also signed a the Personal Information Utilization Agreement form. However, for those who have already received the drug before the beginning of the investigation, only the subjects whose medical record can be used are included.
Exclusion criteria
1. Subjects who is hypersensitive to the active ingredient or additives of this drug 2. Subjects who have severe hepatopathy 3. Subjects who have severe renal disorder (creatinine clearance\<30mL/min) or a terminal renal disease treated by dialysis 4. Subjects who received a combined treatment of fluvoxamine 5. Subjects who have genetic problems, such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change from baseline to week 48 in the percentage of the predicted FVC | up to 48 weeks | In case of administering this drug for more than 12 weeks after registration in the investigation, response evaluation is conducted every 12 weeks (12,24,36,48 weeks) and records are investigated before administration of this drug and after 12, 24,36,48 weeks of administration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse event after this drug administration in general medical | 48 weeks | Any adverse events occurred after this drug dosing will be recorded. Description of adverse event(s) including type of adverse event(s), onset/end date, severity, action taken, causal relationship to the drug and investigator's view on the adverse event(s) will be captured, whether it is related to the drug or not and until follow up visit more than 1 time during the surveillance period. Lab abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be adverse events. |
Outcome results
None listed